|Grant Affiliation:||Lewis: Ab Specificity & Fc-Mediated Protection|
|Strategy:||Prophylactic neutralizing Ab|
|Study Type:||Antibody Screening|
|Study Start Date:||2012-04-03|
|Study Made Public:||2014-10-22|
Specificity of anti-gp41 monoclonal antibodies that mediate ADCC
CAVD 360 is an immunogenicity study to define the epitopes recognized by a panel of anti-gp41 monoclonal antibodies that mediate ADCC.
Sign in to see full information about this study and to download study data.
ProductsNo Products used in study
No integrated data is available for this study.
No non-integrated data is available for this study.